INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 145 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 1.70 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $138,000 | -96.6% | 10,000 | -96.0% | 0.01% | -95.5% |
| Q4 2021 | $4,072,000 | +21.7% | 250,000 | +11.0% | 0.22% | -9.8% |
| Q3 2021 | $3,346,000 | +7.5% | 225,200 | +246.5% | 0.24% | +76.8% |
| Q2 2020 | $3,112,000 | -21.6% | 65,000 | +2.8% | 0.14% | -44.8% |
| Q1 2020 | $3,969,000 | +100.3% | 63,200 | +295.0% | 0.25% | +133.6% |
| Q4 2019 | $1,982,000 | +66.1% | 16,000 | +6.7% | 0.11% | +114.0% |
| Q2 2019 | $1,193,000 | -99.3% | 15,000 | -99.0% | 0.05% | -99.2% |
| Q1 2019 | $162,200,000 | +92.8% | 1,449,900 | +73.7% | 5.97% | +3.6% |
| Q4 2018 | $84,136,000 | +35.0% | 834,600 | +69.3% | 5.77% | +87.1% |
| Q3 2018 | $62,340,000 | +475.9% | 493,000 | +282.2% | 3.08% | +278.2% |
| Q2 2018 | $10,824,000 | – | 129,000 | – | 0.82% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |